Nanoparticle universal coronavirus vaccine and methods of making the same

By using a ferritin nanoparticle platform to tandem different β-coronavirus RBD proteins, a novel COVID-19 vaccine was prepared that demonstrated cross-protection against multiple variants in a mouse model. This solved the problems of immunopathogenicity risk and variant infection associated with existing vaccines, and achieved a highly efficient immune response.

CN115850400BActive Publication Date: 2026-07-07BEIJING GENEVAX BIOTECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
BEIJING GENEVAX BIOTECHNOLOGY CO LTD
Filing Date
2022-12-22
Publication Date
2026-07-07

Smart Images

  • Figure BDA0004012071530000091
    Figure BDA0004012071530000091
  • Figure BDA0004012071530000101
    Figure BDA0004012071530000101
  • Figure BDA0004012071530000111
    Figure BDA0004012071530000111
Patent Text Reader

Abstract

The application discloses a nanoparticle universal new coronavirus vaccine and a preparation method thereof.The nanoparticle universal new coronavirus vaccine disclosed by the application is obtained by mixing a protein shown in SEQ ID No.7 or SEQ ID No.10 in a sequence table with an aluminum adjuvant and a CpG adjuvant.Experiments prove that the nanoparticle universal new coronavirus vaccine of the application can produce antibodies that bind to a new coronavirus in serum after immunizing animals, the vaccine of the application can produce a good cross-protection effect on different new coronavirus mutant strains, and the antigen dose on mice is only 0.05ug.The protein shown in SEQ ID No.7 or SEQ ID No.10 and the vaccine prepared by using the protein have a good application prospect.
Need to check novelty before this filing date? Find Prior Art